Work

Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps1113

Authors: Neelima Vidula, Nora K. Horick, Erica Blouch, Amalia Rivera, Erin Basile, Ruth Fax, Leif W. Ellisen, Hope S. Rugo, Aditya Bardia

Institutions: Massachusetts General Hospital, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Harvard University

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3028642376

Cites:

Cited by: 2

Related to: 10